In CDC Survey of Over 13,000 Children, More Than Half Had

New Post Public Reply Private Reply Replies (0) Message Board
Rusty
213
In CDC Survey of Over 13,000 Children, More Than Half Had ‘Systemic Reaction’ After COVID-19 Vaccine
September 5, 2022

In a CDC survey of over 13,000 children, more than 55 percent of the subjects between the ages of 6 months and two years had a “systemic reaction” in response to their first dose of the Pfizer-BioNTech or Moderna COVID-19 vaccines, the CDC said on Sept. 1.

Parents reported 6 percent of young children were unable to do normal activities after second dose

omicron-slide-one-6-months-2.png

A systemic reaction is a response beyond the injection site. The CDC said almost 60 percent had a systemic reaction to the second dose of the Moderna vaccine.

While the most common systemic reactions were fatigue, fever, irritability, and crying, parents of more than 6 percent of the children in the study said their child was unable to perform normal activities after the second dose of either the Pfizer-BioNTech or Moderna vaccine.

The CDC collected the data through a program called V-Safe—a smartphone-based monitoring system that operates through an app that parents download to their phones.

Between June 18 and Aug. 21, parents of more than 10,000 young children reported reactions to the CDC through V-Safe in the seven days after their child received a COVID-19 vaccination.

Parents of 8,338 children ages six months to 2 years who received the Moderna vaccine reported information through V-Safe, with 55.7 percent reporting a systemic reaction after the first dose and about 58 percent after the second dose. For the Pfizer vaccine, parents of 4,749 children ages six months to 2 years submitted reports showing that 55.8 percent had a systemic reaction after the first dose and about 47 percent after the second dose of the vaccine.

The most frequently reported reactions for children six months to 2 years were irritability or crying, sleepiness, and fever. The most common reactions for children aged 3-5 years were injection site pain, fatigue, and fever.

The data also showed a more serious reaction category labeled “any health impact.”

About 10 percent of all children six months to 2 years were reported to have a “health impact” after getting their first dose of either the Moderna or Pfizer vaccine. For the Moderna vaccine, slightly more children had a health impact after the second dose; for the Pfizer vaccine, it was slightly less.

The information was presented to the CDC’s Advisory Committee on Immunization Practices (ACIP) on Sept. 1 as part of an overview of all data related to the safety of COVID-19 vaccines.

Advertisements
In addition to V-Safe, data was presented summarizing reports from the Vaccine Adverse Event Reporting System (VAERS) and the Vaccine Safety Data Link (VSD), which includes data from several large health maintenance organizations in the United States.

All three systems look at the safety of vaccines after they’ve already gone to market and have been administered to large numbers of people.

Tom Shimabukuro, the head of the CDC’s vaccine safety team, headed the presentation and told committee members that no “statistical signals” of COVID-19 vaccine reactions were found for young children in the VSD data.

Shimabukuro also said that systemic reactions were “commonly reported” following vaccines.

However, other medical professionals like Dr. Meryl Nass from Children’s Health Defense have expressed caution over the reported reactions, pointing to the high number of systemic reaction reports among very young children.

The FDA approved the emergency-use authorization of COVID-19 vaccines for children aged six months to 5 years on June 17. According to the CDC, about 599,460 children in this age group have received the Pfizer-BioNTech vaccine, and about 440,770 have received the Moderna vaccine.

From June 18 through Aug. 31, approximately 1 million doses of the Moderna and Pfizer vaccines were administered to children in this age group.

Read the full story here.
https://www.theepochtimes.com/more-than-half-...07948.html
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hi3D Unlocks AI 3D Model for Open-Source Innovation

Updated Category News Views 3

A New Era in 3D Model Accessibility Unless you’ve been hiding under a rock, it’s hard to miss how digital terraforming has shifted gears. With Hi3D V1.0 opening its doors, the playing field's getting a major reshuffle. Or, as they say, the table is being set, and everyone's getting a seat. By letting loose production-validated AI tools, Hi3D is throwing down the...

Continue Reading
Unicycive's Stock Plunge: Fraud Suit and FDA Hurdles

Updated Category News Views 7

Unicycive's Tumultuous Journey Lately, it's been a rocky road for Unicycive Therapeutics, Inc., with their stock free-falling 39.1% in the span of a heartbeat on June 30, 2026. What sparked this nosedive? The FDA kicked back their revised New Drug Application for a kidney disease treatment yet again, spotlighting old manufacturing issues never nipped in the bud. Talk...

Continue Reading
NYC's Carriage Horse Ban: A New Era for Urban Welfare

Updated Category News Views 4

You've got to hand it to New York City—this isn't just another Tuesday twist. The City Council's decision to nix horse-drawn carriages is like throwing a wrench in an antique machine. It's a bold move in a concrete jungle that's constantly wearing new coats. Tradition vs. Welfare: The Crux For years, the idea of horses prancing down NYC streets seemed like a quaint nod...

Continue Reading
Basic Invite's Holiday Card Service Offers Saving Time

Updated Category News Views 1

Getting the Cards Out: Maneuvering the Holiday Hustle Alright, let's dive into the madness that is holiday card season. Could be a logistical nightmare or a nostalgic tradition, depending on your cup of tea. Basic Invite here is trying to cut through the chaos by bumping deadlines and offering some straight-out-the-gate mailing options. If you play your cards right—pun...

Continue Reading
D-Wave Investors Face Pressure Ahead of December 15

Updated Category News Views 3

Investors Eye December 15 Deadline Nothing like a looming deadline to stir up some anxiety among investors, and that's exactly what's going down at D-Wave Quantum Inc. right now. We're talking about the class action lawsuit spearheaded by the firm Robbins Geller Rudman & Dowd LLP. They've sent out a call to arms for investors who suffered significant losses from February...

Continue Reading
Celebrating Alexander Trost: A Lifetime of Compassionate Care

Updated Category News Views 4

A Legendary Career in Palliative Medicine You know, in a world where people glamorize stock flips and flashy earnings, it's refreshing to spotlight good old-fashioned compassion. Enter Dr. Alexander Trost, DNP, FNP-C, ACHPN. This fella has just been honored as a Pinnacle Lifetime Member by The Inner Circle—a nod to his impactful work in palliative medicine. You ever try...

Continue Reading
Tigo Energy Faces Class Action Over Revenue Claims

Updated Category News Views 3

Trouble Brewing for Tigo Energy? Straight from the horse's mouth, we hear about Tigo Energy (NASDAQ: TYGO) getting embroiled in a class action smackdown. Picture it: Tigo fumbles their projections, and boy does it sting. They're caught in the crossfire for allegedly puffing up their revenue expectations tied to a venture with EG4 Electronics—poised to churn out...

Continue Reading
Rising Food Safety Stars Honored: A Global Effort

Updated Category News Views 2

Food Safety Breakthrough: Youth Leads the Charge When it comes to food safety, it’s about time the younger crowd gets their due. The latest crew to step up to the plate is the Class of 2026's 40 Under 40 Food Safety Professionals. They’re not just pushing paper; these folks are setting the bar high and innovating across continents with real, tangible changes. From...

Continue Reading
Ellington's Q3 Earnings Call: What Investors Need to Know

Updated Category News Views 5

An Anticipated Unveiling Ellington Financial Inc. (NYSE:EFC) is gearing up to spill the beans on its third-quarter financials for 2026. It's all going down after the markets close on November 4th. I can tell you, folks, anyone keeping an eye on EFC will be itching to know what's inside those numbers. With a company this deep into financial assets, reading between the...

Continue Reading
Dott's Q3 2026: Micromobility Growth Soars High

Updated Category News Views 5

Riding the Wave of Profit in Micromobility Sometimes all you need is a quick jolt of genius to turn the wheels of fortune. Dott seems to have hit that sweet spot in Q3 of 2026. Deploying 45,000 new vehicles wasn’t just a logistical feat; it was a calculated bet that paid off handsomely, bolstering their business to soaring heights. Performance that Packs a Punch The Q3...

Continue Reading

Top 5 Most Recently Viewed Articles

ComFree's Remarkable Comeback: A New Era in Real Estate

Updated Category News Views 375

ComFree's Return to the Market After a notable absence, ComFree is back, igniting excitement in the real estate industry. The company's founders, Erin and Travis Holowach, originally created ComFree as a platform for homeowners to sell properties without agent interference, saving them significant fees. Their mission is now revitalized as they reclaim the brand they built...

Continue Reading
Why Capital Gains Tax Planning Matters for Long-Term Investors

Updated Category Investing Views 159

The average federal income tax paid by a typical person ranges from 13.5% to 15%, and tax planning is a mathematical necessity for anyone serious about building long-term wealth in the United States. Every dollar lost to an inefficient exit from an investment is a dollar that stops compounding for your future self. There are thousands of taxable events triggered daily...

Continue Reading
Biomea Fusion Reports Milestone 52-Week Findings in Diabetes

Updated Category News Views 164

Biomea Fusion Unveils Promising Efficacy of Icovamenib Biomea Fusion, Inc. (Nasdaq: BMEA), a pioneer in clinical-stage advancements for diabetes and obesity, recently announced significant 52-week results from its Phase II COVALENT-111 study. This study examined the potential effects of icovamenib, a novel treatment for type 2 diabetes (T2D), and the results underscore a...

Continue Reading
D-Wave Hit with Legal Scrutiny After Disappointing Q2

Updated Category News Views 23

D-Wave Quantum Under Legal Microscope Alright, folks, let's dive headfirst into some dicey financial waters with D-Wave Quantum Inc. (NASDAQ: QBTS). This quantum computing company is finding itself in a bit of a pickle following some rough second-quarter results that left investors scratching their heads. If you bought into the hype and are feeling the sting in your...

Continue Reading
Groundbreaking Debut of DeriW Exchange at Exclusive Event

Updated Category News Views 309

Groundbreaking Launch of DeriW Exchange DeriW, an innovative decentralized perpetual exchange, has officially launched during an exclusive event, showcasing its advanced features and capabilities. The event, hosted by CoinW, attracted 400 influential figures from the cryptocurrency sector. Among the attendees were thought leaders, blockchain pioneers, and affiliates, all...

Continue Reading